DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Clinical trials for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT trials appear
Sign up with your email to follow new studies for DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets deadly brain tumors in early trial
Disease control TerminatedThis early-phase study tests whether adding the experimental drug S-Gboxin to standard radiation and chemotherapy can help people with glioblastoma or diffuse midline glioma, two aggressive brain cancers. About 10 participants whose tumors have returned or worsened will receive t…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: Petrov, Andrey • Aim: Disease control
Last updated May 17, 2026 01:00 UTC
-
Engineered t cells take on deadly childhood brain cancer
Disease control OngoingThis early-phase trial tests a new treatment for people with a rare, aggressive brain tumor called H3.3K27M-mutated diffuse midline glioma. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack the tumor. Before receiving the cells, patients g…
Matched conditions: DIFFUSE MIDLINE GLIOMA, H3 K27M-MUTANT
Phase: PHASE1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 14, 2026 12:05 UTC